Astellas Pharma China Announces Organizational Changes and New Business Unit Establishment

Astellas Pharma China, a leading pharmaceutical company, recently announced significant organizational changes and the establishment of a new business unit. These strategic adjustments aim to enhance market competitiveness, adapt to evolving market dynamics, and capitalize on emerging opportunities in the Chinese healthcare sector. The restructuring involves key executive appointments and the formation of a dedicated China Biopharmaceutical Business Unit (BBU) under the leadership of Lin Xiao, among other noteworthy developments.

Executive Appointments in the Oncology Division:
As part of the restructuring, Mr. Chen Kangwei, General Manager of Astellas Pharma China's Oncology Division, will be returning to Singapore due to family reasons. He will assume the role of Astellas Pharma's Asia Area (AA) BBU Commercial Head, reporting to Sylvia Varela, Vice President of the Asia Area. Concurrently, Mr. Lai Minglong, currently the General Manager of Astellas Pharma China, will take on the additional responsibility of leading the Oncology Division. He will also join Astellas Pharma's Global Oncology Management Team, reporting directly to Wang Lei, President of Astellas Pharma International Business and China.

Establishment of the China Biopharmaceutical Business Unit (BBU):
Astellas Pharma China will officially establish the China Biopharmaceutical Business Unit (BBU), which will be headed by Lin Xiao, who will also be responsible for the Respiratory and Biologics Division and oversee operations in Hong Kong and Macau. The BBU will play a pivotal role in driving the company's growth in the field of chronic diseases in China. Lin Xiao will report directly to Wang Lei, President of Astellas Pharma China.

Strategic Leadership Profiles:
Lai Minglong, with a medical degree from the University of California and a Master's in Public Health from the University of California, Berkeley, assumes the position of General Manager and Oncology Business Unit Head for Astellas Pharma China. He brings in extensive experience from his previous roles as a project leader at a leading consulting firm in Boston and as a Vice President at another pharmaceutical company. Lai Minglong joined Astellas Pharma China in June 2017, initially overseeing the Cardiovascular and Metabolic Business Unit before being promoted to the position of General Manager.

Lin Xiao, a graduate of Zhejiang University, previously held key positions as the Head of Strategic Planning for Asia and Greater China at another pharmaceutical company and as the Market Head of the Core Products Division in China. Lin Xiao joined Astellas Pharma in June 2019 as Assistant Vice President, responsible for renal therapy. He later became Vice President of Astellas Pharma China and assumed the role of Head of the Respiratory and Autoimmune Business Unit.

Astellas Pharma China's recent organizational changes, including executive appointments and the establishment of the China Biopharmaceutical Business Unit, reflect the company's commitment to strengthening its position in the Chinese pharmaceutical market. As the industry undergoes significant transformations, Astellas Pharma is proactively adapting its strategies to capitalize on emerging opportunities. With a focus on innovation, localized research and development, and expanding its product portfolio, Astellas Pharma China aims to accelerate its business growth and establish a robust strategic presence in China's healthcare sector.